SCHEMBL17601894

SCHEMBL17601894

C=CCN(CC(C)c1cc(=O)oc2c(C=O)c(O)ccc12)C(=O)O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERN1 O75460 9/20 0.49
GAA P10253 4/20 0.38
KDM4E B2RXH2 3/20 0.38
ALDH1A1 P00352 3/20 0.38
GLA P06280 2/20 0.38
HPGD P15428 2/20 0.38
SORT1 Q99523 1/20 0.37
MAOB P27338 3/20 0.36
MAOA P21397 2/20 0.36
CA9 Q16790 1/20 0.35
HSD17B10 Q99714 2/20 0.35
GFER P55789 1/20 0.35
TSHR P16473 1/20 0.35
CASP1 P29466 1/20 0.35
CASP7 P55210 1/20 0.35
MGAM O43451 1/20 0.34
LMNA P02545 1/20 0.34
TP53 P04637 1/20 0.34
CYP3A4 P08684 1/20 0.34
MAPT P10636 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17601906 0.89 ERN1 (0.47) ERN1GAAKDM4EALDH1A1GLA
SCHEMBL17601899 0.82 AKR1B1 (0.44) GAAKDM4EALDH1A1GLAHPGD
SCHEMBL17601911 0.81 ERN1 (0.58) ERN1GAAKDM4EALDH1A1GLA
SCHEMBL17601908 0.79 ERN1 (0.58) ERN1GAAKDM4EALDH1A1GLA
SCHEMBL16197846 0.77 ERN1 (0.58) ERN1GAAKDM4EALDH1A1GLA
SCHEMBL14924884 0.76 ERN1 (0.69) ERN1GAAKDM4EALDH1A1GLA
SCHEMBL30848910 0.75 ERN1 (0.68) ERN1GAAKDM4EALDH1A1GLA
SCHEMBL17601907 0.70 HSD17B3 (0.44) GAAKDM4EALDH1A1GLAHPGD
SCHEMBL16197785 0.69 ERN1 (0.56) ERN1GAAKDM4EALDH1A1GLA
SCHEMBL30848924 0.68 ERN1 (0.66) ERN1KDM4EALDH1A1HPGDMAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10323013-B2 Inhibitors of the IRE-1/XBP-1 pathway and methods of using thereof H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) 2019-06-18 US disclosed
US-20160083361-A1 INHIBITORS OF THE IRE-1/XBP-1 PATHWAY AND METHODS OF USING THEREOF H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. 2016-03-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10323013-B2 Inhibitors of the IRE-1/XBP-1 pathway and methods of using thereof XBP1, ERN1, SREBF1 ERN1 2/4885GAA 3369/4885KDM4E 2963/4885
US-20160083361-A1 INHIBITORS OF THE IRE-1/XBP-1 PATHWAY AND METHODS OF USING THEREOF XBP1, RRP1B, ERN1 ERN1 3/4885GAA 2533/4885KDM4E 3704/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.